Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100
- PMID: 14726411
- DOI: 10.1161/01.ATV.0000117174.19078.85
Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100
Abstract
Objective: The aim of this study was to investigate the molecular mechanism for changes in proteoglycan binding and LDL receptor affinity on two compositional changes in LDL that have been associated with atherosclerosis: cholesterol enrichment of the core and modification by secretory group IIA phospholipase A2 (sPLA2) of the surface.
Methods and results: Transgenic mice expressing recombinant apolipoprotein (apo) B and sPLA2 were generated. Recombinant LDL were isolated and tested for their proteoglycan and LDL receptor-binding activity. The results show site A (residues 3148-3158) in apoB100 becomes functional in sPLA2-modified LDL and that site A acts cooperatively with site B (residues 3359-3369), the primary proteoglycan-binding site in native LDL, in the binding of sPLA2-modified LDL to proteoglycans. Our results also show that cholesterol enrichment of LDL is associated with increased affinity for proteoglycans and for the LDL receptor. This mechanism is likely mediated by a conformational change of site B and is independent of site A in apoB100.
Conclusions: Site A in apoB100 becomes functional in sPLA2-modified LDL and acts cooperatively with site B resulting in increased proteoglycan-binding activity. The increased binding for proteoglycans of cholesterol-enriched LDL is solely dependent on site B.
Similar articles
-
Identification of the proteoglycan binding site in apolipoprotein B48.J Biol Chem. 2002 Aug 30;277(35):32228-33. doi: 10.1074/jbc.M204053200. Epub 2002 Jun 17. J Biol Chem. 2002. PMID: 12070165
-
Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.J Clin Invest. 1998 Jun 15;101(12):2658-64. doi: 10.1172/JCI2265. J Clin Invest. 1998. PMID: 9637699 Free PMC article.
-
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis.Nature. 2002 Jun 13;417(6890):750-4. doi: 10.1038/nature00804. Nature. 2002. PMID: 12066187
-
Phospholipase A2 and small, dense low-density lipoprotein.Curr Opin Lipidol. 2000 Oct;11(5):465-71. doi: 10.1097/00041433-200010000-00004. Curr Opin Lipidol. 2000. PMID: 11048889 Review.
-
Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis.J Intern Med. 2005 Nov;258(5):395-410. doi: 10.1111/j.1365-2796.2005.01556.x. J Intern Med. 2005. PMID: 16238675 Review.
Cited by
-
Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes.Curr Cardiol Rep. 2009 Nov;11(6):445-51. doi: 10.1007/s11886-009-0064-2. Curr Cardiol Rep. 2009. PMID: 19863869 Review.
-
Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL.J Lipid Res. 2009 Apr;50(4):641-50. doi: 10.1194/jlr.M800450-JLR200. Epub 2008 Dec 3. J Lipid Res. 2009. PMID: 19056705 Free PMC article.
-
Punicalagin Induces Serum Low-Density Lipoprotein Influx to Macrophages.Oxid Med Cell Longev. 2016;2016:7124251. doi: 10.1155/2016/7124251. Epub 2016 Jul 19. Oxid Med Cell Longev. 2016. PMID: 27516832 Free PMC article.
-
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia.Nat Rev Cardiol. 2022 Sep;19(9):577-592. doi: 10.1038/s41569-022-00676-y. Epub 2022 Mar 22. Nat Rev Cardiol. 2022. PMID: 35318466 Review.
-
The small leucine-rich repeat proteoglycans in tissue repair and atherosclerosis.J Intern Med. 2015 Nov;278(5):447-61. doi: 10.1111/joim.12400. J Intern Med. 2015. PMID: 26477596 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous